Pep IQ
← Pep IQ
Preclinical work exists in rodent models showing BDNF upregulation, dendritic spine density changes, and cognitive performance effects under chronic dosing (typically 7–21 days). Adamax is built on the Semax peptide structure with an adamantane modification for stability — the published animal evidence base for Adamax specifically is small, with most of the data coming from related Semax-family work.
Community protocols converge on 300–600 mcg once daily, intranasal or subcutaneous, in 14–21 day cycles followed by 7+ days off. Subcutaneous gives 85–92% bioavailability vs ~45–60% intranasal. Morning dosing within 60 minutes of waking is preferred to align with cortisol rhythm. Cycling is required because the related Russian intranasal peptides show modest tolerance to continuous use.
No published controlled human trials for Adamax specifically. The Semax parent peptide has Russian clinical literature for stroke and cognitive applications (Semax 12–18 mg/day intranasal in Russian stroke protocols), but Western RCT data for either Semax or Adamax remains thin. WADA does not currently list Adamax.
Not approved as a medicine in any Western country. Sourcing is via research-peptide vendors. Long-term human safety data does not exist — effects are extrapolated from Semax research and short community use reports.
Adamax is a structurally enhanced Semax derivative with promising mechanism (BDNF, melanocortin pathways) but limited published evidence of its own. Community protocol of 300–600 mcg daily for 14–21 days then break is what's converged on, with the explicit caveat that the actual evidence base is the Semax family rather than Adamax-specific RCTs. Pep IQ flags this as a less-evidenced compound — the protocol is plausible but not validated.
Adamax represents the next generation of Semax derivatives — taking a compound that was already a deliberate improvement on ACTH, and engineering it further to address Semax's two main pharmacokinetic limitations: rapid enzymatic degradation and incomplete blood-brain barrier penetration.
The modification is structural: an adamantane group — a cage-like carbon structure derived from the P21 peptide — is attached at the C-terminus, and the N-terminus is acetylated, producing the sequence Ac-MEHFPGP-AG-NH₂. Adamantane is not a biological molecule — it's an organic compound known for its exceptional chemical stability and lipophilicity, properties that translate directly into improved enzymatic resistance and BBB crossing efficiency.
The result is described as the most potent Semax derivative available. But this is where the honest assessment must be clear: Adamax-specific published research is extremely limited. The effects attributed to it are almost entirely extrapolated from Semax's extensive literature, combined with known pharmacokinetic logic about what improved stability and BBB penetration would produce if the core mechanism is the same.
Critical caveat before reading further: Unlike Semax (30 years of research, clinical approval) or Selank (RCT data), Adamax has no published human trials and very limited direct preclinical data. The benefits listed in this entry reflect what would be expected from an improved Semax delivery system — they are not directly demonstrated for Adamax itself. Read accordingly.
Understanding Adamax requires understanding what the adamantane modification actually does pharmacokinetically, and why that matters for a nootropic peptide.
The extrapolation problem: Pharmacokinetic improvements are real and chemically logical. But improved delivery does not automatically mean improved outcomes — it depends on whether the dose-response curve is still on the ascending slope, whether the mechanism of action scales linearly, and whether there are off-target effects at higher effective doses. None of this has been directly studied in Adamax. The mechanism is plausible. The efficacy is assumed.
Adamax is the least-characterised rung of the Semax ladder — far less real-world feedback than Semax or N-Acetyl Semax Amidate (NASA), and what feedback exists is inconsistent. A more elaborate molecule is not automatically a stronger one: many users find well-dosed NASA more reliable than Adamax despite its simpler structure. And because Adamax sits at the exotic end of the market, the biggest practical variable is rarely the pharmacology — it's whether the vial actually holds well-characterised Adamax at all.